Harmony Biosciences Q2 FY26 net income rises 90% to $75.4 million; revenue climbs 30% to $261.3 million
HRMY•Pipeline update
- BP-205 Phase 1 SAD data showed favorable PK and safety.
- Phase 1 MAD data are expected in Q4, with a Phase 1b study starting in Q3.
Second-quarter results and guidance
- Harmony Biosciences posted Q2 net product revenue of $261.3 million, up 30% year over year, with average patients rising 450 to 8,950.
- Net income climbed to $75.4 million; diluted EPS rose to $1.28.
- Cost of product sold increased 66% to $63.2 million, lifting it to 24.2% of net product revenue due to new Novitium license royalties.
- The company reiterated 2026 WAKIX net revenue guidance of $1.0 billion to $1.04 billion, and said it had $962.5 million in cash, cash equivalents and investments at June 30.
Related News
Wacker Biotech, Eclipsebio form strategic collaboration on RNA therapeutics development, manufacturing
XLV•
Exagen Q2 FY26 net loss narrows 28% to $3.2 million; revenue rises 16% to $19.9 million
XGN•
